

VIA HAND DELIVERY MARCH 9, 2001

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: **COLEMAN et al.**

Application Serial No.: 08/972,301


Art Unit: 1646

Filed: November 18, 1997

Examiner: Kemmerer, E.

For: **Endothelial Monocyte Activating
Polypeptide III**

Attorney Docket No.: PF206D1



STATEMENT UNDER 37 C.F.R. §§1.821 AND 1.825

Commissioner for Patents
Washington, D.C. 20231


Sir:

Pursuant to 37 C.F.R. §§1.821(f) and 1.825(b), Applicants hereby certify that the sequence listing information recorded in computer readable form and submitted herewith is identical to the written (on paper) Second Substitute Sequence Listing submitted herewith.

Applicants further certify under 37 C.F.R. §§1.821(g) and 1.825(a) that the Second Substitute Sequence Listing submitted herewith contains no new matter.

Respectfully submitted,

Dated: March 9, 2001


Mark J. Hyman
Attorney for Applicants

(Reg. No. 46,789)

Human Genome Sciences, Inc.
9410 Key West Avenue
Rockville, MD 20850
Telephone: (240) 314-1224

Enclosures